{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:32:39Z","timestamp":1785522759843,"version":"3.56.0"},"publisher-location":"Cham","reference-count":67,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032228994","type":"print"},{"value":"9783032229007","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/164_2025_781","type":"book-chapter","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:56:43Z","timestamp":1765825003000},"page":"83-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the Biologic Activity of Different Species of Heparin"],"prefix":"10.1007","author":[{"given":"Walter","family":"Jeske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"781_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10760296211052293","volume":"27","author":"A Al-Hakim","year":"2021","unstructured":"Al-Hakim A (2021) General considerations for diversifying heparin drug products by improving the current heparin manufacturing process and reintroducing bovine sourced heparin to the US market. Clin Appl Thromb Hemost 27:1\u201314","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"781_CR2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1378\/chest.88.6.878","volume":"88","author":"JE Ansell","year":"1985","unstructured":"Ansell JE, Price JM, Shah S, Beckner RR (1985) Heparin-induced thrombocytopenia. What is the real frequency? Chest 88(6):878\u2013882","journal-title":"Chest"},{"key":"781_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1160\/TH09-11-0761","volume":"103","author":"RS Aquino","year":"2010","unstructured":"Aquino RS, Pereira MS, Vairo BC, Cinelli LP, Santos GRC, Fonseca RJC, Mourao PAS (2010) Heparins from porcine and bovine intestinal mucosa: are they similar drugs? Thromb Haemost 103:1005\u20131015","journal-title":"Thromb Haemost"},{"key":"781_CR4","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1021\/bi00394a024","volume":"26","author":"DH Atha","year":"1987","unstructured":"Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J (1987) Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry 26:6454\u20136461","journal-title":"Biochemistry"},{"key":"781_CR5","first-page":"147","volume":"45","author":"C Bal dit Sollier","year":"2020","unstructured":"Bal dit Sollier C, Dillinger JG, Drouet L (2020) Anticoagulant activity and pleiotropic effects of heparin. JMV-J Med Vasc 45:147\u2013157","journal-title":"JMV-J Med Vasc"},{"issue":"12","key":"781_CR6","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.drudis.2020.09.011","volume":"25","author":"SN Baytas","year":"2020","unstructured":"Baytas SN, Linhardt RJ (2020) Advances in the preparation and synthesis of heparin and related products. Drug Discov Today 25(12):2095\u20132109","journal-title":"Drug Discov Today"},{"issue":"7","key":"781_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/1076029616685430","volume":"23","author":"S Bertini","year":"2017","unstructured":"Bertini S, Fareed J, Madaschi RG, Torri G, Naggi A (2017) Characterization of PF4-Heparin complexes by photon correlation spectroscopy and zeta potential. Clin Appl Thromb Hemost 23(7):725\u2013734","journal-title":"Clin Appl Thromb Hemost"},{"key":"781_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/pharmaceutics15041115","volume":"15","author":"FF Bezerra","year":"2023","unstructured":"Bezerra FF, Oliviera SNMCG, Sales RA, Piquet AA, Capille NV, Vilanova A, Tovar AMF, Mourao PAS (2023) Approaches to assure similarity between pharmaceutical heparins from two different manufacturers. Pharmaceutics 15:1115","journal-title":"Pharmaceutics"},{"issue":"4","key":"781_CR9","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/0002-9378(95)91362-9","volume":"173","author":"LR Brancazio","year":"1995","unstructured":"Brancazio LR, Roperti KA, Stierer R, Laifer SA (1995) Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 173(4):1240\u20131245","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"781_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0008-6215(94)00172-3","volume":"263","author":"B Casu","year":"1994","unstructured":"Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Totti G, Oreste P, Tursi F, Zoppetti G, Lindahl U (1994) Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E coli K5. Carbohydr Res 263(2):271\u2013284","journal-title":"Carbohydr Res"},{"issue":"12","key":"781_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/glycob\/cwh128","volume":"14","author":"M Cesaretti","year":"2004","unstructured":"Cesaretti M, Luppi E, Maccari F, Volpi N (2004) Isolation and characterization of a heparin with high anticoagulant activity from the clam Tapes phylippinarum: evidence for the presence of a high content of antithrombin III binding site. Glycobiology 14(12):1275\u20131284","journal-title":"Glycobiology"},{"key":"781_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1076029619840701","volume":"25","author":"J Chen","year":"2019","unstructured":"Chen J, Yu Y, Fareed J, Hoppensteadt D, Jeske W, Kouta A, Jin C, Jin Y, You Y, Xia K, Zhang F, Chen S, Ye X, Linhardt RJ (2019) Comparison of low-molecular-weight heparins prepared from ovine heparins with enoxaparin. Clin Appl Thromb Hemost 25:1\u20139","journal-title":"Clin Appl Thromb Hemost"},{"issue":"26","key":"781_CR13","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1182\/blood-2010-06-292938","volume":"116","author":"SL Chudasama","year":"2010","unstructured":"Chudasama SL, Espinasse B, Hwang F, Qi R, Joglekar M, Afonina G, Wiesner MR, Welsby IJ, Ortel TL, Arepally GM (2010) Heparin modifies the immunogenicity of positively charged proteins. Blood 116(26):6046\u20136053","journal-title":"Blood"},{"issue":"3","key":"781_CR14","first-page":"235","volume":"33","author":"FA De Lima Torres","year":"2020","unstructured":"De Lima Torres FA, Torres ACB, Ribeiro A, Maia CO, Almeida FP, Roceto J, Matkovski JA, Kovalski MG, Pizato VA, Cordeiro TMG (2020) A retrospective study on unfractionated bovine heparin safety in in-pump cardiac surgery. Int J Cardiovasc Sci 33(3):235\u2013242","journal-title":"Int J Cardiovasc Sci"},{"issue":"5","key":"781_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/bja\/aex044","volume":"118","author":"X Delavenne","year":"2017","unstructured":"Delavenne X, Ollier E, Chollet S, Sandri S, Lanoisel\u00e9e J, Hodin S, Montmartin A, Fuzellier JF, Mismetti P, Gergel\u00e9 L (2017) Pharmacokinetic\/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass. Br J Aenesth 118(5):705\u2013712","journal-title":"Br J Aenesth"},{"key":"781_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0304-4165(85)90041-8","volume":"843","author":"CP Dietrich","year":"1985","unstructured":"Dietrich CP, de Paiva JF, Moraes CT, Takahashi HK, Porcionatto MA, Nader HB (1985) Isolation and characterization of a heparin with high anticoagulant activity from Anomalocardia brasiliana. Biochem et Biophys Acta 843:1\u20137","journal-title":"Biochem et Biophys Acta"},{"key":"781_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0304-4165(99)00087-2","volume":"1428","author":"CP Dietrich","year":"1999","unstructured":"Dietrich CP, Paiva JF, Castro RAB, Chavante SF, Jeske W, Fareed J, Gorin PAJ, Mendes A, Nader HB (1999) Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Biochem Biophys Acta 1428:273\u2013283","journal-title":"Biochem Biophys Acta"},{"issue":"14","key":"781_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315586121","volume":"121","author":"D Douaisi","year":"2024","unstructured":"Douaisi D, Paskaleva EE, Fu L, Grover N, McManaman CL, Varghese S, Brodfuehrer PR, Gibson JM, de Joode I, Xia K, Brier MI, Simmons TJ, Datta P, Zhang F, Onishi A, Hirakane M, Mori D, Linhardt RJ, Dordick JS (2024) Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin. PNAS 121(14):e2315586121","journal-title":"PNAS"},{"key":"781_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/0049-3848(87)90391-4","volume":"48","author":"RM Emanuele","year":"1987","unstructured":"Emanuele RM, Fareed J (1987) The effect of molecular weight on the bioavailability of heparin. Thromb Res 48:591\u2013596","journal-title":"Thromb Res"},{"key":"781_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev.biochem.71.110601.135458","volume":"71","author":"JD Esko","year":"2002","unstructured":"Esko JD, Selleck SB (2002) Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71:435\u2013471","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"781_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0003-4975(02)04349-7","volume":"75","author":"JL Francis","year":"2003","unstructured":"Francis JL, Palmer GJ, Moroose R, Drexler A (2003) Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75(1):17\u201322","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"781_CR22","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/jps.23501","volume":"102","author":"L Fu","year":"2013","unstructured":"Fu L, Li G, Yang B, Onishi A, Li L, Sun P, Zhang F, Linhardt RJ (2013) Structural characterization of pharmaceutical heparins prepared from different animal tissues. J Pharm Sci 102(5):1447\u20131457","journal-title":"J Pharm Sci"},{"key":"781_CR23","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1021\/acs.jmedchem.7b01269","volume":"60","author":"L Fu","year":"2017","unstructured":"Fu L, Mori D, Hirakane M, Lin L, Grover N, Datta P, Yu Y, Zhao J, Zhang F, Yalcin M, Mousa SA, Dordick JS, Linhardt RJ (2017) Enzymatic generation of highly anticoagulant bovine intestinal heparin. J Med Chem 60:8673\u20138679","journal-title":"J Med Chem"},{"key":"781_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijcard.2016.08.033","volume":"223","author":"WJ Gomes","year":"2016","unstructured":"Gomes WJ, Leal JC, Braile DM, Guimaraes JA, Lopes RD, Lima MA, Nader HB (2016) A Brazilian perspective foe the use of bovine heparin in open heart surgery. Int J Cardiol 223:611\u2013612","journal-title":"Int J Cardiol"},{"issue":"7","key":"781_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/hq0701.093686","volume":"21","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Anand SS, Halperin JL, Fuster V (2001) Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 21(7):1094\u20131096","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"781_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1042\/bj2370573","volume":"237","author":"P Hovingh","year":"1986","unstructured":"Hovingh P, Piepkorn M, Linker A (1986) Biologic implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates. Biochem J 237:573\u2013581","journal-title":"Biochem J"},{"issue":"3","key":"781_CR28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1172\/JCI111028","volume":"72","author":"RE Hurst","year":"1983","unstructured":"Hurst RE, Poon MC, Griffith MJ (1983) Structure-activity relationships of heparin. Independence of heparin charge density and antithrombin-binding domains in thrombin inhibition by antithrombin and heparin cofactor II. J Clin Invest 72(3):1042\u20131045","journal-title":"J Clin Invest"},{"issue":"9S","key":"781_CR29","doi-asserted-by":"publisher","first-page":"150S","DOI":"10.1177\/1076029618798956","volume":"24","author":"W Jeske","year":"2018","unstructured":"Jeske W, Kouta A, Duff R, Rangnekar V, Niverthi M, Hoppensteadt D, Fareed J, Yao Y (2018) Comparative pharmacokinetic profile of 3 batches of ovine low-molecular-weight heparin and 1 batch of branded enoxaparin. Clin Appl Thromb Hemost 24(9S):150S\u2013156S","journal-title":"Clin Appl Thromb Hemost"},{"key":"781_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fmed.2018.00360","volume":"5","author":"W Jeske","year":"2019","unstructured":"Jeske W, Kouta A, Farooqui A, Siddiqui F, Rangnekar V, Niverthi M, Laddu R, Hoppensteadt D, Iqbal O, Walenga J, Fareed J (2019) Bovine mucosal heparins are comparable to porcine mucosal heparin at USP potency adjusted levels. Front Med 5:360. https:\/\/doi.org\/10.3389\/fmed.2018.00360","journal-title":"Front Med"},{"issue":"2","key":"781_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/0003-9861(86)90524-2","volume":"248","author":"RE Jordan","year":"1986","unstructured":"Jordan RE, Marcum JA (1986) Anticoagulantly active heparin from clam (Mercenaria mercenaria). Arch Biochem Biophys 248(2):690\u2013695","journal-title":"Arch Biochem Biophys"},{"key":"781_CR32","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/S0003-4975(01)02534-6","volume":"71","author":"BA Konkle","year":"2001","unstructured":"Konkle BA, Bauer TL, Arepally G, Cines DB, Poncz M, McNulty S, Edie RN, Mannion JD (2001) Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Ann Thorac Surg 71:1920\u20131924","journal-title":"Ann Thorac Surg"},{"key":"781_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1076029619889406","volume":"25","author":"A Kouta","year":"2019","unstructured":"Kouta A, Jeske W, Hoppensteadt D, Iqbal O, Yao Y, Fareed J (2019) Comparative pharmacological profiles of various bovine, ovine and porcine heparins. Clin Appl Thromb Hemost 25:1\u20139","journal-title":"Clin Appl Thromb Hemost"},{"key":"781_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1076029620951851","volume":"26","author":"A Kouta","year":"2020","unstructured":"Kouta A, Hoppensteadt D, Bontekoe E, Jeske W, Duff R, Cera L, Fareed J (2020) Studies on tissue factor pathway inhibitor antigen release by bovine, ovine and porcine heparins following intravenous administration to non-human primates. Clin Appl Thromb Hemost 26:1\u20138","journal-title":"Clin Appl Thromb Hemost"},{"key":"781_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1051\/ject\/2023026","volume":"55","author":"MH Lee","year":"2023","unstructured":"Lee MH, Beck M, Shann K (2023) Protamine dose to neutralize heparin at the completion of cardiopulmonary bypass can be reduced significantly without affecting post-operative bleeding. J Extra Corpor Technol 55:105\u2013111","journal-title":"J Extra Corpor Technol"},{"issue":"3","key":"781_CR36","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1021\/jm030176m","volume":"46","author":"RJ Linhardt","year":"2003","unstructured":"Linhardt RJ (2003) Claude S. Hudson award address in carbohydrate chemistry. Heparin: structure and activity. J Med Chem 46(3):2551\u20132564","journal-title":"J Med Chem"},{"issue":"6","key":"781_CR37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1177\/1076029616686422","volume":"23","author":"X Liu","year":"2017","unstructured":"Liu X, St. Ange K, Fareed J, Hoppensteadt D, Jeske W, Kouta A, Chi L, Jin C, Jin Y, Yao Y, Linhardt RJ (2017) Comparison of low-molecular-weight heparins prepared from bovine heparins with enoxaparin. Clin Appl Thromb Hemost 23(6):542\u2013553","journal-title":"Clin Appl Thromb Hemost"},{"key":"781_CR38","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1021\/bm049196b","volume":"6","author":"E Luppi","year":"2005","unstructured":"Luppi E, Cesaretti M, Volpi N (2005) Purification and characterization of heparin from the Italian clam Callista chione. Biomacromolecules 6:1672\u20131678","journal-title":"Biomacromolecules"},{"key":"781_CR39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.thromres.2007.07.004","volume":"122","author":"S Middeldorp","year":"2008","unstructured":"Middeldorp S (2008) Heparin: from animal organ extract to designer drug. Thromb Res 122:753\u2013762","journal-title":"Thromb Res"},{"key":"781_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/pr.115.011247","volume":"68","author":"B Mulloy","year":"2015","unstructured":"Mulloy B, Hogwood J, Gray E, Lever R, Page CP (2015) Pharmacology of heparin and related drugs. Pharmacol Rev 68:76\u2013141","journal-title":"Pharmacol Rev"},{"key":"781_CR41","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1055\/a-1946-0325","volume":"6","author":"SNMCG Oliveira","year":"2022","unstructured":"Oliveira SNMCG, Tovar AMF, Bezerra FF, Piquet AA, Capille NV, Santos PS, Vilanova E, Mourao PAS (2022) Anticoagulant activity of heparins from different animal sources are driven by a synergistic combination of physical-chemical factors. TH Open 6:e309\u2013e322","journal-title":"TH Open"},{"key":"781_CR42","doi-asserted-by":"publisher","first-page":"23111","DOI":"10.1021\/acsomega.4c02128","volume":"9","author":"SNMCG Oliveira","year":"2024","unstructured":"Oliveira SNMCG, Bezerra FF, Piquet AA, Sales RA, Valle GCT, Capille NV, Tovar AMF, Mourao PAS (2024) A unique enoxaparin derived from bovine intestinal heparin: a single purification step of the starting material assures a bovine enoxaparin like the standard from porcine origin. ACS Omega 9:23111\u201323120","journal-title":"ACS Omega"},{"key":"781_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/pgr2.70025","volume":"3","author":"SNMCG Oliviera","year":"2025","unstructured":"Oliviera SNMCG, Bezerra FF, Pereira MS, Tovar AMF, Aquino RS, Mourao PAS (2025) Global use of bovine heparin: challenges and opportunities. Proteoglycan Res 3:e70025","journal-title":"Proteoglycan Res"},{"key":"781_CR44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jpba.2018.10.052","volume":"164","author":"Y Ouyang","year":"2019","unstructured":"Ouyang Y, Han X, Yu Y, Chen J, Fu L, Zhang F, Linhardt RJ, Fareed J, Hoppensteadt D, Jeske W, Kouta A, Zhang Z, Xia K (2019) Chemometric analysis of porcine, bovine and ovine heparins. J Pharam Biomed Anal 164:345\u2013352","journal-title":"J Pharam Biomed Anal"},{"key":"781_CR45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0300-9629(94)00021-K","volume":"111A","author":"JF Paiva","year":"1995","unstructured":"Paiva JF, Santos EA, Jeske W, Fareed J, Nader HB, Dietrich CP (1995) A comparative analysis on the mechanism of the anticoagulant action of mollusc and mammalian heparins. Comp Biochem Physiol 111A:495\u2013499","journal-title":"Comp Biochem Physiol"},{"issue":"24","key":"781_CR46","doi-asserted-by":"publisher","first-page":"11413","DOI":"10.1016\/S0021-9258(18)60822-1","volume":"262","author":"G Pejler","year":"1987","unstructured":"Pejler G, Danielsson A, Bjork I, Lindahl U, Nader HB, Dietrich CP (1987) Structure and antithrombin-binding properties of heparin isolated from the clams Anomalocardia brasiliana and Tivela mactroides. J Biol Chem 262(24):11413\u201311421","journal-title":"J Biol Chem"},{"key":"781_CR47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/blood-2004-04-1544","volume":"105","author":"L Rauova","year":"2005","unstructured":"Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS (2005) Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131\u2013138","journal-title":"Blood"},{"issue":"11","key":"781_CR48","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.drudis.2014.07.004","volume":"19","author":"GRC Santos","year":"2014","unstructured":"Santos GRC, Tovar AMF, Capille NVM, Pereira MS, Pomin VH, Mourao PAS (2014) Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs. Drug Discov Today 19(11):1801\u20131807","journal-title":"Drug Discov Today"},{"key":"781_CR49","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12010-008-8498-3","volume":"160","author":"R Saravanan","year":"2010","unstructured":"Saravanan R, Shanmugam A (2010) Isolation and characterization of low molecular weight glycosaminoglycans from marine mollusc Amussium pleuronectus (Linne) using chromatography. Appl Biochem Biotechnol 160:791\u2013799","journal-title":"Appl Biochem Biotechnol"},{"key":"781_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/10826068.2010.488998","volume":"40","author":"R Saravanan","year":"2010","unstructured":"Saravanan R, Vairamani S, Shanmugam A (2010) Glycosaminoglycans from marine clam Meretrix meretrix (Linne.) are an anticoagulant. Prep Biochem Biotechnol 40:305\u2013315","journal-title":"Prep Biochem Biotechnol"},{"key":"781_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2023.120779","volume":"311","author":"Y Song","year":"2023","unstructured":"Song Y, Kouta A, Cera LM, Xia K, Zhang F, Kraemer R, Fareed J, Linhardt RJ, Jeske W (2023) Absolute pharmacokinetics of heparin in primates. Carbohydr Polym 311:120779","journal-title":"Carbohydr Polym"},{"issue":"6","key":"781_CR52","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/1076029616643822","volume":"22","author":"K St Ange","year":"2016","unstructured":"St Ange K, Onishi A, Fu L, Sun X, Lin L, Mori D, Zhang F, Dordick JS, Fareed J, Hoppensteadt D, Jeske W, Linhardt RJ (2016) Analysis of heparins derived from bovine tissues and comparison to porcine intestinal heparins. Clin Appl Thromb Hemost 22(6):520\u2013527","journal-title":"Clin Appl Thromb Hemost"},{"key":"781_CR53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ymben.2022.01.002","volume":"70","author":"BE Thacker","year":"2022","unstructured":"Thacker BE, Thorne KJ, Cartwright C, Park J, Glass K, Chea A, Kellman BP, Lewis NE, Wang Z, Di Nardo A, Sharfstein ST, Jeske W, Walenga J, Hogwood J, Gray E, Mulloy B, Esko JD, Glass CA (2022) Multiplex genome editing of mammalian cells for producing recombinant heparin. Metab Eng 70:155\u2013165","journal-title":"Metab Eng"},{"key":"781_CR54","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1756-0500-6-230","volume":"6","author":"AMF Tovar","year":"2013","unstructured":"Tovar AMF, Teixeira LAC, Rembold SM, Leite M, Lugon JR, Mourao PAS (2013) Bovine and porcine heparins: different drugs with similar effects on human haemodialysis. BMC Res Notes 6:230","journal-title":"BMC Res Notes"},{"key":"781_CR55","doi-asserted-by":"publisher","first-page":"35619","DOI":"10.1038\/srep35619","volume":"6","author":"AMF Tovar","year":"2016","unstructured":"Tovar AMF, Santos GRC, Capille NV, Piquet AA, Glauser BF, Pereira MS, Vilanova E, Mourao PAS (2016) Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs. Sci Rep 6:35619","journal-title":"Sci Rep"},{"key":"781_CR56","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1055\/s-0039-1678663","volume":"119","author":"AMF Tovar","year":"2019","unstructured":"Tovar AMF, Vairo BC, Oliveira SNMCG, Glauser BF, Santos GRC, Capille NV, Piquet AA, Santana PS, Micheli KVA, Pereira MS, Vilanova E, Mourao PAS (2019) Converting the distinct heparins sourced from bovine or porcine mucosa into a single anticoagulant drug. Thromb Haemost 119:618\u2013632","journal-title":"Thromb Haemost"},{"issue":"2","key":"781_CR57","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0049-3848(94)90066-3","volume":"75","author":"S Valentin","year":"1994","unstructured":"Valentin S, Larnkjer A, Ostergaard P, Nielsen JI, Nordfang O (1994) Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 75(2):173\u2013183","journal-title":"Thromb Res"},{"key":"781_CR58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fmed.2019.00016","volume":"6","author":"E Vilanova","year":"2019","unstructured":"Vilanova E, Vairo BC, Oliveira SNMCG, Glauser BF, Capille NV, Santos GRC, Tovar AMF, Pereira MS, Mourao PAS (2019) Heparins sourced from bovine and porcine mucosa gain exclusive monographs in the Brazilian pharmacopeia. Front Med 6:16","journal-title":"Front Med"},{"key":"781_CR59","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1021\/bm0505033","volume":"6","author":"N Volpi","year":"2005","unstructured":"Volpi N, Maccari F (2005) Glycosaminoglycans composition of the large freshwater mollusc bivalve Anodonta anodonta. Biomacromolecules 6:3174\u20133180","journal-title":"Biomacromolecules"},{"issue":"Suppl 1","key":"781_CR60","first-page":"2351","volume":"134","author":"J Walenga","year":"2016","unstructured":"Walenga J, Jeske W, Bertini S, Risi G, Sung M, Farooqui A, Bacher C, Hoppensteadt D, Iqbal O, Lewis B, Bakhos M (2016) Bovine heparin demonstrates the same interaction with HIT antibodies as porcine heparin. Blood 134(Suppl 1):2351","journal-title":"Blood"},{"key":"781_CR61","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1021\/acs.analchem.1c04965","volume":"94","author":"Z Wang","year":"2022","unstructured":"Wang Z, Arnold K, Dhurandahare VM, Xu Y, Pagadala V, Labra E, Jeske W, Fareed J, Gearing M, Liu J (2022) Analysis of 3-O-sulfated heparan sulfate using isotopically labeled oligosaccharide calibrants. Anal Chem 94:2950\u20132957","journal-title":"Anal Chem"},{"key":"781_CR62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1096-4959(03)00247-1","volume":"136","author":"M Warda","year":"2003","unstructured":"Warda M, Gouda EM, Toida T, Chi L, Linhardt RJ (2003a) Isolation and characterization of raw heparin from dromedary intestine: evaluation of a new source of pharmaceutical heparin. Comp Biochem Physiol Part C 136:357\u2013365","journal-title":"Comp Biochem Physiol Part C"},{"key":"781_CR63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1096-4959(02)00250-6","volume":"134","author":"M Warda","year":"2003","unstructured":"Warda M, Mao W, Toida T, Linhardt RJ (2003b) Turkey intestine as a commercial source of heparin? Comparative structural studies of intestinal avian and mammalian glycosaminoglycans. Comp Biochem Physiol Part B 134:189\u2013197","journal-title":"Comp Biochem Physiol Part B"},{"issue":"28","key":"781_CR64","doi-asserted-by":"publisher","first-page":"8241","DOI":"10.1007\/s00216-016-9940-y","volume":"408","author":"U Warttinger","year":"2016","unstructured":"Warttinger U, Giese C, Harenberg J, Holmer E, Kr\u00e4mer R (2016) A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma. Anal Bioanal Chem 408(28):8241\u20138251","journal-title":"Anal Bioanal Chem"},{"key":"781_CR65","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.carbpol.2018.05.070","volume":"197","author":"S Xie","year":"2018","unstructured":"Xie S, Guan Y, Zhu P, Yu M, Linhardt RJ, Chi L, Jin L (2018) Preparation of low molecular weight heparins from bovine and ovine heparins using nitrous acid degradation. Carbohydr Polym 197:83\u201391","journal-title":"Carbohydr Polym"},{"key":"781_CR66","doi-asserted-by":"publisher","unstructured":"Xu Y, Chandarajoti K, Zhang X, Pagadala V, Dou W, Hoppensteadt DM, Sparkenbaugh EM, Cooley B, Daily S, Key NS, Severynse-Stevens D, Fareed J, Linhardt RJ, Pawlinski R, Liu J (2017) Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. Sci Transl Med 9(406). https:\/\/doi.org\/10.1126\/scitranslmed.aan5954","DOI":"10.1126\/scitranslmed.aan5954"},{"issue":"34","key":"781_CR67","doi-asserted-by":"publisher","first-page":"29054","DOI":"10.1074\/jbc.M112.358523","volume":"287","author":"Y Yu","year":"2012","unstructured":"Yu Y, Pempe EH, Liu J (2012) Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities. J Biol Chem 287(34):29054\u201329061","journal-title":"J Biol Chem"},{"key":"781_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.122216","volume":"339","author":"Y Yu","year":"2024","unstructured":"Yu Y, Song Y, Zhao Y, Wang N, Wei B, Linhardt RJ, Dordick JS, Zhang F, Wang H (2024) Quality control, safety assessment and preparation approaches of low molecular weight heparin. Carbohydr Polym 339:122216","journal-title":"Carbohydr Polym"}],"container-title":["Handbook of Experimental Pharmacology","Antithrombotic and Antiplatelet Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2025_781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T20:02:17Z","timestamp":1777060937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2025_781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783032228994","9783032229007"],"references-count":67,"URL":"https:\/\/doi.org\/10.1007\/164_2025_781","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"16 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}